Are you using tarlatamab for neuroendocrine carcinomas (NECs) and poorly differentiated neuroendocrine tumors of GI (non-lung) origins?
Is it your preferred second-line therapy for metastatic small cell (non-lung primary) that has progressed on chemoimmunotherapy (carboplatin, etoposide, and atezolizumab), who are platinum-resistant (progressed less than 6 months)?
Community PollStarted
Are you using tarlatamab for extrapulmonary neuroendocrine carcinomas (epNECs) who have progressed on platinum doublet +/- IO?
73 physicians have voted
Join Mednetto vote and see how they answered.
1 Answer
Mednet MemberInvited Expert
Medical Oncology · Mayo Clinic
Answered on · Updated on
We have treated a few patients with DLL3+ extrapulmonary NECs (epNECs) with tarlatamab, but we have not reported our experience yet. There have been responses, but mostly short-lived, but I know of cases where the responses were more durable than one would expect in epNECs progressing on first-line ...
Join for free or sign in to see the full answer